Key statistics
On Monday, BeOne Medicines AG (6160:HKG) closed at 152.50, -14.33% below its 52-week high of 178.00, set on Apr 01, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 150.50 |
---|---|
High | 153.10 |
Low | 148.40 |
Bid | 152.50 |
Offer | 152.70 |
Previous close | 154.10 |
Average volume | 5.09m |
---|---|
Shares outstanding | 1.54bn |
Free float | 1.45bn |
P/E (TTM) | -- |
Market cap | 248.50bn HKD |
EPS (TTM) | -2.24 HKD |
Data delayed at least 15 minutes, as of Jul 14 2025 09:08 BST.
More ▼
Press releases
- European Commission Approves TEVIMBRA® in Combination with Chemotherapy as a First-Line Treatment for Nasopharyngeal Carcinoma
- BeOne Medicines Showcases Groundbreaking Oncology Pipeline at R&D Day
- BeOne Medicines Receives Positive CHMP Opinion for Tablet Formulation of BRUKINSA®
- BeOne Medicines Showcases Breakthrough Data in CLL and MCL at EHA 2025
- U.S. FDA Approves Tablet Formulation of BeOne’s BRUKINSA® for All Approved Indications
- BeOne Medicines to Host Investor R&D Day Webcast on June 26, 2025
- BeOne Medicines Unveils Promising Clinical Data for Two Novel Breast Cancer Therapies at ASCO 2025
- BeOne Medicines Presents New SEQUOIA Study Results Reinforcing BRUKINSA’s Differentiated Profile with or without Venetoclax in Frontline CLL at ASCO 2025
- BeOne Medicines Launches Following Redomiciliation to Switzerland, Marking a New Chapter in Global Oncology
- BeiGene Receives Positive CHMP Opinion for TEVIMBRA® as a First-Line Treatment for Nasopharyngeal Cancer
More ▼